Clinical Trials List
2019-02-28 - 2023-04-30
Phase II
Recruiting8
ICD-10C50
Malignant neoplasm of breast
A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
Novartis Pharmaceuticals
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Audit
None
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HWEI-CHUNG WANG 無
- 黃至豪 未分科
- Chen-Teng Wu 無
- Yao-Chung Wu 無
- Chih-Jung Chen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳佳哲 無
- 林偉哲 無
- 賴香蘭 未分科
- 李易濰 無
- 陳彥豪 無
- Tai-Jan Chiu 無
- Yu-Li Su 無
- 陳彥仰 無
- Shau-Hsuan Li 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林燕淑 未分科
- Jiun-I Lai 未分科
- Chi-Cheng Huang 未分科
- 賴亦貞 未分科
- Yi-Fang Tsai 未分科
- Chun-Yu Liu 未分科
- 邱仁輝 未分科
- Ta-Chung Chao 未分科
- 馮晉榮 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
Audit
None
Taiwan National PI
Co-Principal Investigator
- 周旭桓 無
- Mengting Peng 無
- 沈士哲 無
- Chia-Hui Chu 無
- Chan-Keng Yang 無
- Chi-Chang Yu 無
- Wen-Chi Shen 無
- Wen-Ling Kuo 無
- Yung-Chang Lin 無
The Actual Total Number of Participants Enrolled
2 Recruiting
Audit
None
Co-Principal Investigator
- Ann-Lii Cheng 無
- MING-YANG WANG 無
- Wei-Wu Chen 無
- 陳怡君 無
- WEI-LI MA 未分科
- 林季宏 無
- 張端瑩 無
- 羅喬 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Progression Free Survival [ Time Frame: Up to approximately 34 months ]
Progression-free survival is defined as the time from the date of randomization to the date of the first documented progression as per local review and according to RECIST 1.1 or death due to any cause.
Secondary Outcome Measures :
Time to treatment failure [ Time Frame: Up to approximately 34 months ]
Time to treatment failure is defined as the time from the date of randomization/start of treatment to the earliest of date of progression, date of death due to any cause, change to other anti-cancer therapy, or date of discontinuation due to reasons other than 'Protocol violation' or 'Administrative problems'.
Overall response rate (ORR) [ Time Frame: Up to approximately 34 months ]
Overall response rate (ORR) is defined as the proportion of patients whose best overall response is either complete response (CR) or partial response (PR), as per local review and according to RECIST 1.1.
Clinical benefit rate [ Time Frame: Up to approximately 34 months ]
Clinical benefit rate is defined as the proportion of patients with a best overall response of CR, or PR or stable disease, lasting for a duration of at least 24 weeks, as defined by RECIST 1.1.
Time to response [ Time Frame: Up to approximately 34 months ]
Time to response is defined as the time from the date of randomization to the first documented response of either CR or PR, which must be subsequently confirmed, as defined by RECIST 1.1.
Overall survival [ Time Frame: Up to approximately 46 months ]
Overall survival is defined as the time from the date of randomization to the date of death due to any cause.
Frequency/severity of adverse events, lab abnormalities. [ Time Frame: Up to approximately 46 months ]
Safety of ribociclib in combination with NSAI and goserelin, and combination chemotherapies
Change from baseline in the global health status/QOL scale score by using FACT-B questionnaire [ Time Frame: Up to approximately 46 months ]
Functional Assessment of Cancer Therapy - Breast (FACT-B) will be collected to assess health-related QoL, health status, functioning, disease symptoms, side effects, and cancer-related pain.
Descriptive statistics will be used to summarize the overall score at each scheduled assessment time point. Additionally, change from baseline at the time of each assessment will be summarized.
The distribution of time to definitive 10% deterioration in the global health status from FACT-B questionnaire will be assessed in the two treatment arms. Scores range from 0 to 4. no subscale. 0 score is the worst for social/family and functional wellbeing and 4 is the worst for physical, emotional wellbeing and additional concerns.
3-month treatment failure rate [ Time Frame: Up to approximately 34 months ]
Treatment failure rate is defined as the proportion of patients who discontinued the study treatment due to progressive disease, death due to any cause, change to other anti-cancer therapy, or discontinuation due to reasons other than protocol violation or administrative problems.
Inclution Criteria
1.Patient is an adult female ≥ 18 years old and < 60 years old at the time of informed consent.
2.Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory. ER should be more than 10% ER positive or Allred ≥5 by local laboratory testing.
3.Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1 + or 2 + If IHC is 2 +, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample.
4.Women with inoperable locally advanced or metastatic breast cancer not amenable to curative therapy. Patients must fulfill at least one of the following criteria to be considered that combination chemotherapy is needed according to PI's judgment. However, for patients who are eligible under inoperable locally advanced breast cancer or criteria 4c, the recruitment is stopped to enrich patient population with visceral metastases.
Symptomatic visceral metastases
Rapid progression of disease or impending visceral compromise.
Markedly symptomatic non visceral disease if the treating physician opt to give chemotherapy for rapid palliation of patients symptoms.
5.Patient is premenopausal or perimenopausal at the time of study entry.
a.Premenopausal status is defined as either:
Patient had last menstrual period within the last 12 months. OR
If on tamoxifen within the past 14 days, plasma estradiol and FSH are in the premenopausal range, according to local laboratory definition.
In case of therapy induced amenorrhea, plasma estradiol and/or FSH are in the premenopausal range according to local laboratory definition.
Patients who have undergone bilateral oophorectomy are not eligible.
b.Perimenopausal status is defined as neither premenopausal nor postmenopausal
6.Patients must have not received neither prior hormonal therapy nor chemotherapy for advanced breast cancer, except LHRH agonist. Patients who received ≤ 14 days of tamoxifen or a NSAI (letrozole or anastrozole) with or without LHRH agonist for advanced breast cancer prior to randomization are eligible. Patient must have measurable disease.
Exclusion Criteria
1.Patient has received prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy, or any CDK4/6 inhibitor for advanced breast cancer.
Patients who received (neo) adjuvant therapy for breast cancer are eligible. If the prior neo (adjuvant) therapy included aromatase inhibitors, the treatment free interval must be greater than 12 months from the completion of aromatase inhibitor treatment until randomization.
If patients have disease recurrence during adjuvant tamoxifen treatment, disease free interval (defined as duration between the date of patient received complete tumor resection for primary breast cancer lesion to the date of disease recurrence documented) must be greater than 12 months.
Patients who are receiving ≤ 14 days of tamoxifen or NSAI or LHRH agonists ≤ 28 days for advanced breast cancer prior to randomization are eligible.
2.Patient has received extended-field radiotherapy ≤ 2 weeks prior to randomization or limited field radiotherapy ≤ 2 weeks prior to randomization, and has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion). Patient from whom ≥ 25% of the bone marrow has been previously irradiated are also excluded.
3.Patient has a concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell skin carcinoma or curatively resected cervical cancer in situ.
4.Patients who have lung metastases with oxygen demand in resting status.
5.Patients who have liver metastases with bilirubin > 1.5 ULN.
6.Patients with CNS involvement unless they meet ALL of the following criteria:
At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment.
Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases
Leptomeningeal metastases is not allowed, even with stable clinical condition
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
222 participants
